{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:09:22Z","timestamp":1776276562983,"version":"3.50.1"},"reference-count":89,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0234","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:13:03Z","timestamp":1772093583000},"source":"Crossref","is-referenced-by-count":1,"title":["Drugs for migraine prophylaxis"],"prefix":"10.3238","author":[{"given":"Hans Christoph","family":"Diener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Grans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"10.3238\/arztebl.m2025.0234_ref1","unstructured":"Porst M, Wengler A, Leddin J, et al.: Migraine and tension-type headache in Germany. Prevalence and disease severity from the BURDEN 2020 Burden of Disease Study. J Health Monit 2020; 5: 2\u201324."},{"key":"10.3238\/arztebl.m2025.0234_ref2","doi-asserted-by":"crossref","unstructured":"Diener HC, F\u00f6rderreuther S, Kropp P, Reuter U, et al.: Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne, S1-Leitlinie. DGN und DMKG, in: Deutsche Gesellschaft f\u00fcr Neurologie (eds.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie 2025. www.dgn.org\/leitlinien (last accessed on 19 January 2026).","DOI":"10.1007\/s42451-025-00829-6"},{"key":"10.3238\/arztebl.m2025.0234_ref3","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS): The international classification of headache disorders ICHD-3, 3rd edition. Cephalalgia 2018; 38: 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"10.3238\/arztebl.m2025.0234_ref4","doi-asserted-by":"crossref","unstructured":"Ashina S, Terwindt GM, Steiner TJ, et al.: Medication overuse headache. Nat Rev Dis Primers 2023; 9: 5.","DOI":"10.1038\/s41572-022-00415-0"},{"key":"10.3238\/arztebl.m2025.0234_ref5","doi-asserted-by":"crossref","unstructured":"Ornello R, Caponnetto V, Ahmed F, et al.: Evidence-based guidelines for the pharmacological treatment of migraine, summary version. Cephalalgia 2025; 45: 3331024251321500.","DOI":"10.1177\/03331024251393936"},{"key":"10.3238\/arztebl.m2025.0234_ref6","doi-asserted-by":"crossref","unstructured":"Ornello R, Caponnetto V, Ahmed F, et al.: Evidence-based guidelines for the pharmacological treatment of migraine. Cephalalgia 2025; 45: 3331024241305381.","DOI":"10.1177\/03331024251393936"},{"key":"10.3238\/arztebl.m2025.0234_ref7","doi-asserted-by":"crossref","unstructured":"Puledda F, Sacco S, Diener HC, et al.: International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia 2024; 44: 3331024241269735.","DOI":"10.1177\/03331024241269735"},{"key":"10.3238\/arztebl.m2025.0234_ref8","doi-asserted-by":"crossref","unstructured":"Holroyd KA, Penzien DB, Cordingley GE: Propranolol in the management of recurrent migraine: A meta-analytic review. Headache 1991; 31: 333\u201340.","DOI":"10.1111\/j.1526-4610.1991.hed3105333.x"},{"key":"10.3238\/arztebl.m2025.0234_ref9","doi-asserted-by":"crossref","unstructured":"Silberstein SP, Goadsby PB: Migraine: Preventive treatment. Cephalalgia 2002; 22: 491\u2013512.","DOI":"10.1046\/j.1468-2982.2002.00386.x"},{"key":"10.3238\/arztebl.m2025.0234_ref10","doi-asserted-by":"crossref","unstructured":"Jackson JL, Kuriyama A, Kuwatsuka Y, et al.: Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One 2019; 14: e0212785.","DOI":"10.1371\/journal.pone.0212785"},{"key":"10.3238\/arztebl.m2025.0234_ref11","doi-asserted-by":"crossref","unstructured":"Jackson JL, Cogbill E, Santana-Davila R, et al.: A comparative effectiveness meta-Analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015; 10: e0130733.","DOI":"10.1371\/journal.pone.0130733"},{"key":"10.3238\/arztebl.m2025.0234_ref12","doi-asserted-by":"crossref","unstructured":"Kangasniemi P, Andersen AR, Andersson PG, et al.: Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 1987; 7: 231\u20138.","DOI":"10.1046\/j.1468-2982.1987.0704231.x"},{"key":"10.3238\/arztebl.m2025.0234_ref13","doi-asserted-by":"crossref","unstructured":"Steiner TJ, Joseph R, Hedman C, Clifford Rose F: Metoprolol in the prophylaxis of migraine: parallel group comparison with placebo and dose-ranging follow-up. Headache 1988; 28: 15\u201323.","DOI":"10.1111\/j.1365-2524.1988.hed2801015.x"},{"key":"10.3238\/arztebl.m2025.0234_ref14","doi-asserted-by":"crossref","unstructured":"Linde K, Rossnagel K: Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004: CD003225.","DOI":"10.1002\/14651858.CD003225.pub2"},{"key":"10.3238\/arztebl.m2025.0234_ref15","doi-asserted-by":"crossref","unstructured":"Stubberud A, Flaaen NM, McCrory DC, Pedersen SA, Linde M: Flunarizine as prophylaxis for episodic migraine: A systematic review with meta-analysis. Pain 2019; 160: 762\u201372.","DOI":"10.1097\/j.pain.0000000000001456"},{"key":"10.3238\/arztebl.m2025.0234_ref16","doi-asserted-by":"crossref","unstructured":"Deligianni CI, Sacco S, Ekizoglu E, et al.: European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: Flunarizine. J Headache Pain 2023; 24: 128.","DOI":"10.1186\/s10194-023-01657-3"},{"key":"10.3238\/arztebl.m2025.0234_ref17","doi-asserted-by":"crossref","unstructured":"Lampl C, Versijpt J, Amin FM, et al.: European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 1: Amitriptyline. J Headache Pain 2023; 24: 39.","DOI":"10.1186\/s10194-023-01573-6"},{"key":"10.3238\/arztebl.m2025.0234_ref18","doi-asserted-by":"crossref","unstructured":"Couch JR: Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011; 51: 33\u201351.","DOI":"10.1111\/j.1526-4610.2010.01800.x"},{"key":"10.3238\/arztebl.m2025.0234_ref19","doi-asserted-by":"crossref","unstructured":"Brandes J, Saper J, Diamond M, et al.: Topiramate for migraine prevention: A randomized controlled trial. JAMA 2004; 291: 965\u201373.","DOI":"10.1001\/jama.291.8.965"},{"key":"10.3238\/arztebl.m2025.0234_ref20","doi-asserted-by":"crossref","unstructured":"Diener HC, Tfelt-Hansen P, Dahl\u00f6f C, et al.: Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251: 943\u201350.","DOI":"10.1007\/s00415-004-0464-6"},{"key":"10.3238\/arztebl.m2025.0234_ref21","doi-asserted-by":"crossref","unstructured":"Silberstein SD, Lipton RB, Dodick DW, et al.: Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170\u201380.","DOI":"10.1111\/j.1526-4610.2006.00684.x"},{"key":"10.3238\/arztebl.m2025.0234_ref22","doi-asserted-by":"crossref","unstructured":"Lainez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S: Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol 2007; 14: 900\u20136.","DOI":"10.1111\/j.1468-1331.2007.01869.x"},{"key":"10.3238\/arztebl.m2025.0234_ref23","doi-asserted-by":"crossref","unstructured":"Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ: Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 814\u201323.","DOI":"10.1111\/j.1468-2982.2007.01326.x"},{"key":"10.3238\/arztebl.m2025.0234_ref24","doi-asserted-by":"crossref","unstructured":"Silberstein SD: Topiramate in migraine prevention: A 2016 perspective. Headache 2017; 57: 165\u201378.","DOI":"10.1111\/head.12997"},{"key":"10.3238\/arztebl.m2025.0234_ref25","doi-asserted-by":"crossref","unstructured":"Aurora SK, Dodick DW, Turkel CC, et al.: OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793\u2013803.","DOI":"10.1177\/0333102410364676"},{"key":"10.3238\/arztebl.m2025.0234_ref26","doi-asserted-by":"crossref","unstructured":"Diener HC, Dodick DW, Aurora SK, et al.: OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 804\u201314.","DOI":"10.1177\/0333102410364677"},{"key":"10.3238\/arztebl.m2025.0234_ref27","doi-asserted-by":"crossref","unstructured":"Dodick DW, Turkel CC, DeGryse RE, et al.: OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921\u201336.","DOI":"10.1111\/j.1526-4610.2010.01678.x"},{"key":"10.3238\/arztebl.m2025.0234_ref28","doi-asserted-by":"crossref","unstructured":"Bruijn NRA, Huessler EM, MaassenVanDenBrink A, et al.: Placebo response in acute and prophylactic treatment of migraine: A systematic review and meta-analysis covering 36 years of research. Neurol Clin 2025; 44: 23\u201345.","DOI":"10.1016\/j.ncl.2025.08.011"},{"key":"10.3238\/arztebl.m2025.0234_ref29","doi-asserted-by":"crossref","unstructured":"Silberstein SD, Blumenfeld AM, Cady RK, et al.: OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013; 331: 48\u201356.","DOI":"10.1016\/j.jns.2013.05.003"},{"key":"10.3238\/arztebl.m2025.0234_ref30","doi-asserted-by":"crossref","unstructured":"Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A: Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018; 19: 13.","DOI":"10.1186\/s10194-018-0840-8"},{"key":"10.3238\/arztebl.m2025.0234_ref31","doi-asserted-by":"crossref","unstructured":"Wong HT, Khan R, Buture A, Khalil M, Ahmed F: OnabotulinumtoxinA treatment for chronic migraine in pregnancy: an updated report of real-world headache and pregnancy outcomes over 14 years in Hull. Cephalalgia 2025; 45: 3331024251327387.","DOI":"10.1177\/03331024251327387"},{"key":"10.3238\/arztebl.m2025.0234_ref32","doi-asserted-by":"crossref","unstructured":"Deng H, Li GG, Nie H, et al.: Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine\u2014an updated systematic review and meta-analysis. BMC Neurol 2020; 20: 57.","DOI":"10.1186\/s12883-020-01633-3"},{"key":"10.3238\/arztebl.m2025.0234_ref33","doi-asserted-by":"crossref","unstructured":"Soni P, Chawla E: Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis. Clin Neurol Neurosurg 2021; 209: 106893.","DOI":"10.1016\/j.clineuro.2021.106893"},{"key":"10.3238\/arztebl.m2025.0234_ref34","doi-asserted-by":"crossref","unstructured":"Reuter U, Ehrlich M, Gendolla A, et al.: Erenumab versus topiramate for the prevention of migraine\u2014a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 2022; 42: 108\u2013118.","DOI":"10.1177\/03331024211053571"},{"key":"10.3238\/arztebl.m2025.0234_ref35","doi-asserted-by":"crossref","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P: Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 2023; 43: 03331024231159366.","DOI":"10.1177\/03331024231159366"},{"key":"10.3238\/arztebl.m2025.0234_ref36","doi-asserted-by":"crossref","unstructured":"Mistry H, Naghdi S, Brown A, et al.: Preventive drug treatments for adults with chronic migraine: A systematic review with economic modelling. Health Technol Assess 2024; 28: 1\u2013329.","DOI":"10.3310\/AYWA5297"},{"key":"10.3238\/arztebl.m2025.0234_ref37","doi-asserted-by":"crossref","unstructured":"Tepper SJ, Lipton RB, Silberstein SD, et al.: Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis. Headache 2023; 63: 730\u201342.","DOI":"10.1111\/head.14536"},{"key":"10.3238\/arztebl.m2025.0234_ref38","doi-asserted-by":"crossref","unstructured":"Frank F, Ulmer H, Sidoroff V, Broessner G: CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis. Cephalalgia 2021; 41: 1222\u201339.","DOI":"10.1177\/03331024211018137"},{"key":"10.3238\/arztebl.m2025.0234_ref39","doi-asserted-by":"crossref","unstructured":"Diener HC, Rizzoli P: Chronic migraine and medication overuse. Handb Clin Neurol 2023; 198: 187\u2013200.","DOI":"10.1016\/B978-0-12-823356-6.00008-1"},{"key":"10.3238\/arztebl.m2025.0234_ref40","doi-asserted-by":"crossref","unstructured":"Alpuente A, Torres-Ferrus M, Terwindt GM: Preventive CGRP-targeted therapies for chronic migraine with and without medication-overuse headache. Cephalalgia 2023; 43: 03331024221150235.","DOI":"10.1177\/03331024221150235"},{"key":"10.3238\/arztebl.m2025.0234_ref41","doi-asserted-by":"crossref","unstructured":"Tepper SJ, Dodick DW, Lanteri-Minet M, et al.: Efficacy and safety of erenumab for nonopioid medication overuse headache in chronic migraine: A phase 4, randomized, placebo-controlled trial. JAMA Neurology 2024; 81: 1140\u20139.","DOI":"10.1001\/jamaneurol.2024.3043"},{"key":"10.3238\/arztebl.m2025.0234_ref42","doi-asserted-by":"crossref","unstructured":"Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM: Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to onabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol 2022; 12: 788159.","DOI":"10.3389\/fneur.2021.788159"},{"key":"10.3238\/arztebl.m2025.0234_ref43","doi-asserted-by":"crossref","unstructured":"Wang X, Chen Y, Song J, You C: Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: A systematic review and network meta-analysis. Front Pharmacol 2021; 12: 649143.","DOI":"10.3389\/fphar.2021.649143"},{"key":"10.3238\/arztebl.m2025.0234_ref44","doi-asserted-by":"crossref","unstructured":"Wang Q, Liu J, Sun H, et al.: Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database. Expert Opin Drug Saf 2024; 23: 107\u201317.","DOI":"10.1080\/14740338.2023.2250720"},{"key":"10.3238\/arztebl.m2025.0234_ref45","doi-asserted-by":"crossref","unstructured":"Ailani J, Burch RC, Robbins MS, the board of directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 2021; 61: 1021\u201339.","DOI":"10.1111\/head.14153"},{"key":"10.3238\/arztebl.m2025.0234_ref46","doi-asserted-by":"crossref","unstructured":"Overeem LH, Peikert A, Hofacker MD, et al.: Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 2022; 42: 291\u2013301.","DOI":"10.1177\/03331024211048765"},{"key":"10.3238\/arztebl.m2025.0234_ref47","doi-asserted-by":"crossref","unstructured":"McAllister P, Winner PK, Ailani J, et al.: Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: Secondary results from the randomized controlled RELIEF study. J Headache Pain 2022; 23: 22.","DOI":"10.1186\/s10194-021-01376-7"},{"key":"10.3238\/arztebl.m2025.0234_ref48","doi-asserted-by":"crossref","unstructured":"Ashina M, Goadsby PJ, Reuter U, et al.: Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 2021; 28: 1716\u201325.","DOI":"10.1111\/ene.14715"},{"key":"10.3238\/arztebl.m2025.0234_ref49","doi-asserted-by":"crossref","unstructured":"Raffaelli B, De Icco R, Corrado M, Terhart M, Ailani J: Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review. Cephalalgia 2023; 43: 03331024221137091.","DOI":"10.1177\/03331024221137091"},{"key":"10.3238\/arztebl.m2025.0234_ref50","doi-asserted-by":"crossref","unstructured":"Moore E, Bell IM, Fraley ME, et al.: Pharmacologic characterization of atogepant: A potent and selective calcitonin gene-related peptide receptor antagonist. Cephalalgia 2024; 44: 3331024231226186.","DOI":"10.1177\/03331024231226186"},{"key":"10.3238\/arztebl.m2025.0234_ref51","doi-asserted-by":"crossref","unstructured":"Boinpally R, Shebley M, Trugman JM: Atogepant: mechanism of action, clinical and translational science. Clin Transl Sci 2024; 17: e13707.","DOI":"10.1111\/cts.13707"},{"key":"10.3238\/arztebl.m2025.0234_ref52","doi-asserted-by":"crossref","unstructured":"Ailani J, Lipton RB, Goadsby PJ, et al.: Atogepant for the preventive treatment of migraine. N Engl J Med 2021; 385: 695\u2013706.","DOI":"10.1056\/NEJMoa2035908"},{"key":"10.3238\/arztebl.m2025.0234_ref53","doi-asserted-by":"crossref","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, et al.: Atogepant for the preventive treatment of chronic migraine (PROGRESS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 402: 775\u201385.","DOI":"10.1016\/S0140-6736(23)01049-8"},{"key":"10.3238\/arztebl.m2025.0234_ref54","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Friedman DI, Holle-Lee D, et al.: Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology 2024; 103: e209584.","DOI":"10.1212\/WNL.0000000000209584"},{"key":"10.3238\/arztebl.m2025.0234_ref55","doi-asserted-by":"crossref","unstructured":"Croop R, Lipton RB, Kudrow D, et al.: Oral rimegepant for preventive treatment of migraine: A phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 2021: 397: 51\u201360.","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"10.3238\/arztebl.m2025.0234_ref56","doi-asserted-by":"crossref","unstructured":"Schwedt TJ, Myers Oakes TM, Martinez JM, et al.: Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: results from a randomized, controlled clinical trial. Neurol Ther 2024; 13: 85\u2013105.","DOI":"10.1007\/s40120-023-00562-w"},{"key":"10.3238\/arztebl.m2025.0234_ref57","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Dodick DW, Ailani J, et al.: Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol 2020; 19: 727\u201337.","DOI":"10.1016\/S1474-4422(20)30234-9"},{"key":"10.3238\/arztebl.m2025.0234_ref58","doi-asserted-by":"crossref","unstructured":"Tassorelli C, Nagy K, Pozo-Rosich P, et al.: Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): A randomised, placebo-controlled, phase 3b trial. Lancet Neurol 2024; 23: 382\u201392.","DOI":"10.1016\/S1474-4422(24)00025-5"},{"key":"10.3238\/arztebl.m2025.0234_ref59","doi-asserted-by":"crossref","unstructured":"Ashina M, Saper J, Cady R, et al.: Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020; 40: 241\u201354.","DOI":"10.1177\/0333102420905132"},{"key":"10.3238\/arztebl.m2025.0234_ref60","doi-asserted-by":"crossref","unstructured":"Sun H, Dodick DW, Silberstein S, et al.: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15: 382\u201390.","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"10.3238\/arztebl.m2025.0234_ref61","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al.: A controlled trial of erenumab for episodic migraine. N Engl J Med 2017; 377: 2123\u201332.","DOI":"10.1056\/NEJMoa1705848"},{"key":"10.3238\/arztebl.m2025.0234_ref62","doi-asserted-by":"crossref","unstructured":"Dodick DW, Ashina M, Brandes JL, et al.: ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018; 38: 1026\u201337.","DOI":"10.1177\/0333102418759786"},{"key":"10.3238\/arztebl.m2025.0234_ref63","doi-asserted-by":"crossref","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, et al.: A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache 2019; 59: 1731\u201342.","DOI":"10.1111\/head.13652"},{"key":"10.3238\/arztebl.m2025.0234_ref64","doi-asserted-by":"crossref","unstructured":"Wang SJ, Roxas AA, Jr., Saravia B, et al.: Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: the EMPOwER study. Cephalalgia 2021; 41: 1285\u201397.","DOI":"10.1177\/03331024211024160"},{"key":"10.3238\/arztebl.m2025.0234_ref65","doi-asserted-by":"crossref","unstructured":"Takeshima T, Sakai F, Hirata K, et al.: Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Headache 2021; 61: 927\u201335.","DOI":"10.1111\/head.14138"},{"key":"10.3238\/arztebl.m2025.0234_ref66","doi-asserted-by":"crossref","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, et al.: Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018; 392: 2280\u20137.","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"10.3238\/arztebl.m2025.0234_ref67","doi-asserted-by":"crossref","unstructured":"Bigal ME, Dodick DW, Rapoport AM, et al.: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015; 14: 1081\u201390.","DOI":"10.1016\/S1474-4422(15)00249-5"},{"key":"10.3238\/arztebl.m2025.0234_ref68","doi-asserted-by":"crossref","unstructured":"Dodick DW, Silberstein SD, Bigal ME, et al.: Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial. JAMA 2018; 319: 1999\u20132008.","DOI":"10.1001\/jama.2018.4853"},{"key":"10.3238\/arztebl.m2025.0234_ref69","doi-asserted-by":"crossref","unstructured":"Sakai F, Suzuki N, Kim BK, et al.: Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 2021; 61: 1102\u201311.","DOI":"10.1111\/head.14178"},{"key":"10.3238\/arztebl.m2025.0234_ref70","doi-asserted-by":"crossref","unstructured":"Ferrari MD, Diener HC, Ning X, et al.: Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 2019; 394: 1030\u201340.","DOI":"10.1016\/S0140-6736(19)31946-4"},{"key":"10.3238\/arztebl.m2025.0234_ref71","doi-asserted-by":"crossref","unstructured":"Skljarevski V, Oakes TM, Zhang Q, et al.: Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: A randomized clinical trial. JAMA Neurol 2018; 75: 187\u201393.","DOI":"10.1001\/jamaneurol.2017.3859"},{"key":"10.3238\/arztebl.m2025.0234_ref72","doi-asserted-by":"crossref","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. JAMA Neurol 2018; 75: 1080\u20138.","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"10.3238\/arztebl.m2025.0234_ref73","doi-asserted-by":"crossref","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY: Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38: 1442\u201354.","DOI":"10.1177\/0333102418779543"},{"key":"10.3238\/arztebl.m2025.0234_ref74","doi-asserted-by":"crossref","unstructured":"Sakai F, Ozeki A, Skljarevski V: Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial. Cephalalgia Reports 2020; 3.","DOI":"10.1177\/2515816320932573"},{"key":"10.3238\/arztebl.m2025.0234_ref75","doi-asserted-by":"crossref","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, et al.: Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): A multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2020; 19: 814\u201325.","DOI":"10.1016\/S1474-4422(20)30279-9"},{"key":"10.3238\/arztebl.m2025.0234_ref76","doi-asserted-by":"crossref","unstructured":"Hu B, Li G, Li X, et al.: Galcanezumab in episodic migraine: The phase 3, randomized, double-blind, placebo-controlled PERSIST study. J Headache Pain 2022; 23: 90.","DOI":"10.1186\/s10194-022-01458-0"},{"key":"10.3238\/arztebl.m2025.0234_ref77","doi-asserted-by":"crossref","unstructured":"MaassenVanDenBrink A, Terwindt GM, Cohen JM, et al.: Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: Results of the randomized, placebo-controlled, phase 3b FOCUS study. J Headache Pain 2021; 22: 152.","DOI":"10.1186\/s10194-021-01336-1"},{"key":"10.3238\/arztebl.m2025.0234_ref78","doi-asserted-by":"crossref","unstructured":"Dodick DW, Lipton RB, Silberstein S, et al.: Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia 2019; 39: 1075\u201385.","DOI":"10.1177\/0333102419858355"},{"key":"10.3238\/arztebl.m2025.0234_ref79","doi-asserted-by":"crossref","unstructured":"Lipton RB, Goadsby PJ, Smith J, et al.: Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020; 94: e1365\u2013e77.","DOI":"10.1212\/WNL.0000000000009169"},{"key":"10.3238\/arztebl.m2025.0234_ref80","doi-asserted-by":"crossref","unstructured":"Tepper S, Ashina M, Reuter U, et al.: Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16: 425\u201334.","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"10.3238\/arztebl.m2025.0234_ref81","doi-asserted-by":"crossref","unstructured":"Yu S, Kim BK, Wang H, et al.: A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain 2022; 23: 146.","DOI":"10.1186\/s10194-022-01514-9"},{"key":"10.3238\/arztebl.m2025.0234_ref82","doi-asserted-by":"crossref","unstructured":"Bigal ME, Edvinsson L, Rapoport AM, et al.: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 2015; 14: 1091\u2013100.","DOI":"10.1016\/S1474-4422(15)00245-8"},{"key":"10.3238\/arztebl.m2025.0234_ref83","doi-asserted-by":"crossref","unstructured":"Silberstein SD, Dodick DW, Bigal ME, et al.: Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017; 377: 2113\u201322.","DOI":"10.1056\/NEJMoa1709038"},{"key":"10.3238\/arztebl.m2025.0234_ref84","doi-asserted-by":"crossref","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK: Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018; 91: e2211\u2013e21.","DOI":"10.1212\/WNL.0000000000006640"},{"key":"10.3238\/arztebl.m2025.0234_ref85","doi-asserted-by":"crossref","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al.: Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2022; 21: 597\u2013607.","DOI":"10.1016\/S1474-4422(22)00185-5"},{"key":"10.3238\/arztebl.m2025.0234_ref86","doi-asserted-by":"crossref","unstructured":"Lipton RB, Ramirez Campos V, Roth-Ben Arie Z, et al.: Fremanezumab for the treatment of patients with migraine and comorbid major depressive disorder: The UNITE randomized clinical trial. JAMA Neurol 2025; 82: 560\u20139.","DOI":"10.1001\/jamaneurol.2025.0806"},{"key":"10.3238\/arztebl.m2025.0234_ref87","doi-asserted-by":"crossref","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, et al.: The comparative effectiveness of migraine preventive drugs: A systematic review and network meta-analysis. J Headache Pain 2023; 24: 56.","DOI":"10.1186\/s10194-023-01594-1"},{"key":"10.3238\/arztebl.m2025.0234_ref88","doi-asserted-by":"crossref","unstructured":"Raffaelli B, Terhart M, Overeem LH, et al.: Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: A prospective, longitudinal cohort study. Cephalalgia 2022; 42: 326\u201334.","DOI":"10.1177\/03331024211046617"},{"key":"10.3238\/arztebl.m2025.0234_ref89","doi-asserted-by":"crossref","unstructured":"Terhart M, Mecklenburg J, Neeb L, et al.: Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain 2021; 22: 158.","DOI":"10.1186\/s10194-021-01368-7"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:13:22Z","timestamp":1772093602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":89,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0234","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}